Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.
Aging
Frailty
HIV
Physical function
SPPB
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
09 07 2020
09 07 2020
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
11
3
2021
Statut:
ppublish
Résumé
People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, hospitalizations, and death. Identifying factors associated with physical function impairment and frailty can help target interventions. The REPRIEVE trial enrolled participants 40-75 years of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with low to moderate cardiovascular disease risk. We conducted a cross-sectional analysis of those concurrently enrolled in the ancillary study PREPARE at enrollment. Among the 266 participants, the median age was 51 years; 81% were male, and 45% were black, and 28% had hypertension. Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 25 to <30 in 38% and ≥30 in 30%, 33% had a high waist circumference, 89% were physically inactive, 37% (95% confidence interval, 31%, 43%) had physical function impairment (Short Physical Performance Battery score ≤10), and 6% (4%, 9%) were frail and 42% prefrail. In the adjusted analyses, older age, black race, greater BMI, and physical inactivity were associated with physical function impairment; depression and hypertension were associated with frailty or prefrailty. Physical function impairment was common among middle-aged PWH; greater BMI and physical inactivity are important modifiable factors that may prevent further decline in physical function with aging. NCT02344290.
Sections du résumé
BACKGROUND
People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, hospitalizations, and death. Identifying factors associated with physical function impairment and frailty can help target interventions.
METHODS
The REPRIEVE trial enrolled participants 40-75 years of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with low to moderate cardiovascular disease risk. We conducted a cross-sectional analysis of those concurrently enrolled in the ancillary study PREPARE at enrollment.
RESULTS
Among the 266 participants, the median age was 51 years; 81% were male, and 45% were black, and 28% had hypertension. Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 25 to <30 in 38% and ≥30 in 30%, 33% had a high waist circumference, 89% were physically inactive, 37% (95% confidence interval, 31%, 43%) had physical function impairment (Short Physical Performance Battery score ≤10), and 6% (4%, 9%) were frail and 42% prefrail. In the adjusted analyses, older age, black race, greater BMI, and physical inactivity were associated with physical function impairment; depression and hypertension were associated with frailty or prefrailty.
CONCLUSIONS
Physical function impairment was common among middle-aged PWH; greater BMI and physical inactivity are important modifiable factors that may prevent further decline in physical function with aging.
CLINICAL TRIALS REGISTRATION
NCT02344290.
Identifiants
pubmed: 32645163
pii: 5869456
doi: 10.1093/infdis/jiaa249
pmc: PMC7347078
doi:
Banques de données
ClinicalTrials.gov
['NCT02344290']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
S52-S62Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069424
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069463
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054366
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL123339
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069463
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106701
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL123336
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):484-9
pubmed: 23143526
Am Heart J. 2019 Jun;212:1-12
pubmed: 30928823
JAMA Intern Med. 2014 Aug;174(8):1263-70
pubmed: 24911216
AIDS. 2014 Nov 28;28(18):2711-9
pubmed: 25493597
Circ Res. 2019 Jun 7;124(12):e121-e122
pubmed: 31170055
AIDS. 2019 May 1;33(6):931-939
pubmed: 30946147
JAMA. 2016 Nov 15;316(19):2008-2024
pubmed: 27838722
J Antimicrob Chemother. 2020 Jul 1;75(7):1972-1980
pubmed: 32240298
N Engl J Med. 1995 Mar 2;332(9):556-61
pubmed: 7838189
AIDS. 2006 Apr 24;20(7):1003-10
pubmed: 16603852
Am Heart J. 2019 Jun;212:23-35
pubmed: 30928825
Am J Cardiovasc Drugs. 2017 Oct;17(5):375-389
pubmed: 28364370
Am J Cardiol. 2014 Oct 15;114(8):1215-6
pubmed: 25171803
AIDS. 2017 Oct 23;31(16):2287-2294
pubmed: 28991026
Osteoporos Sarcopenia. 2017 Sep;3(3):128-131
pubmed: 30775517
Antivir Ther. 2009;14(6):853-8
pubmed: 19812448
Obes Facts. 2013;6(1):9-16
pubmed: 23434893
AIDS. 2016 Nov 28;30(18):2805-2813
pubmed: 27662545
AIDS Res Hum Retroviruses. 2016 Apr;32(4):311-6
pubmed: 26477698
Lancet HIV. 2017 Jul;4(7):e284-e294
pubmed: 28416195
J Appl Physiol (1985). 2006 Feb;100(2):609-14
pubmed: 16223978
J Infect Dis. 2017 Mar 15;215(6):933-937
pubmed: 28453849
BMC Health Serv Res. 2008 Dec 30;8:278
pubmed: 19115992
Cleve Clin J Med. 2011 Jun;78(6):393-403
pubmed: 21632911
J Physiol. 2015 Mar 1;593(5):1239-57
pubmed: 25620655
J Acquir Immune Defic Syndr. 2012 Jul 1;60 Suppl 1:S1-18
pubmed: 22688010
J Nutr Educ Behav. 2006 Sep-Oct;38(5):286-92
pubmed: 16966049
Clin Infect Dis. 2019 Oct 14;:
pubmed: 31606734
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
J Am Geriatr Soc. 2005 Oct;53(10):1675-80
pubmed: 16181165
Antivir Ther. 2019;24(5):383-387
pubmed: 31032811
J Am Geriatr Soc. 2019 May;67(5):1085-1095
pubmed: 30589075
Aging (Albany NY). 2018 Jan 20;10(1):144-153
pubmed: 29356686
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
JBI Database System Rev Implement Rep. 2018 Mar;16(3):752-775
pubmed: 29521871
Skelet Muscle. 2012 Jun 07;2(1):10
pubmed: 22676806
J Gerontol A Biol Sci Med Sci. 2001 Oct;56(10):M644-9
pubmed: 11584038
QJM. 2009 Sep;102(9):625-33
pubmed: 19633029
J Am Geriatr Soc. 2003 Mar;51(3):314-22
pubmed: 12588574
Phys Ther. 2020 Jan 23;100(1):90-98
pubmed: 31612228
Clin Infect Dis. 2019 Sep 27;69(8):1370-1376
pubmed: 30590451
J Gerontol A Biol Sci Med Sci. 2011 Sep;66(9):1030-8
pubmed: 21719610
J Gerontol A Biol Sci Med Sci. 2015 Dec;70(12):1542-7
pubmed: 26386010
PLoS One. 2014 Mar 24;9(3):e92842
pubmed: 24663122
HIV Clin Trials. 2012 Nov-Dec;13(6):324-34
pubmed: 23195670
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Toxicol Pathol. 2014 Jul;42(5):811-22
pubmed: 24067671
Clin Infect Dis. 2018 Jun 1;66(12):1918-1927
pubmed: 29293942
Arch Phys Med Rehabil. 2014 Apr;95(4):753-769.e3
pubmed: 24291597
PLoS One. 2017 Jan 6;12(1):e0169184
pubmed: 28060856
Age Ageing. 1996 Sep;25(5):386-91
pubmed: 8921145
J Am Geriatr Soc. 2016 Jan;64(1):144-50
pubmed: 26782864
AIDS. 2017 Aug 24;31(13):1831-1838
pubmed: 28590329
Curr HIV/AIDS Rep. 2016 Dec;13(6):340-348
pubmed: 27549318
Clin Chem. 2019 Jan;65(1):80-86
pubmed: 30504259
JAMA Cardiol. 2016 Nov 1;1(8):929-937
pubmed: 27557332
J Geriatr Phys Ther. 2017 Jan/Mar;40(1):42-50
pubmed: 26428899